2024
Testing the feasibility, acceptability, and preliminary efficacy of integrating accommodation strategies into an HIV prevention intervention for people who inject drugs with cognitive dysfunction
Mistler C, Shrestha R, Copenhaver M. Testing the feasibility, acceptability, and preliminary efficacy of integrating accommodation strategies into an HIV prevention intervention for people who inject drugs with cognitive dysfunction. Journal Of Substance Use And Addiction Treatment 2024, 169: 209582. PMID: 39551147, DOI: 10.1016/j.josat.2024.209582.Peer-Reviewed Original ResearchHIV prevention interventionsOpioid use disorderBehavioral HIV prevention interventionHIV prevention informationPreventive interventionsCognitive profile of individualsIntervention contentActive control conditionPrevention informationPreliminary efficacyControl conditionEnhanced HIV prevention interventionPreventive intervention conditionHIV risk reduction informationProfile of individualsHIV-related risk behaviorsRisk of HIVRisk reduction skillsAccommodation strategiesRisk reduction informationPre-exposure prophylaxisCognitive profileUse disorderCognitive dysfunctionIntervention conditionT73 Application of the Multiphase Optimization Strategy (MOST) to Optimize HIV Prevention Targeting People on Medication for Opioid Use Disorder (MOUD) who Have Cognitive Dysfunction: A Study Protocol
Copenhaver M, Mistler C, Shrestha R. T73 Application of the Multiphase Optimization Strategy (MOST) to Optimize HIV Prevention Targeting People on Medication for Opioid Use Disorder (MOUD) who Have Cognitive Dysfunction: A Study Protocol. Drug And Alcohol Dependence 2024, 260: 110522. DOI: 10.1016/j.drugalcdep.2023.110522.Peer-Reviewed Original ResearchHigher methadone dose at time of release from prison predicts linkage to maintenance treatment for people with HIV and opioid use disorder transitioning to the community in Malaysia
Ahmad A, Bromberg D, Shrestha R, Salleh N, Bazazi A, Kamarulzaman A, Shenoi S, Altice F. Higher methadone dose at time of release from prison predicts linkage to maintenance treatment for people with HIV and opioid use disorder transitioning to the community in Malaysia. International Journal Of Drug Policy 2024, 126: 104369. PMID: 38484531, PMCID: PMC11056294, DOI: 10.1016/j.drugpo.2024.104369.Peer-Reviewed Original ResearchMethadone maintenance treatmentNational Institute of Drug AbuseMethadone dosePost-releaseOpioid dependenceMaintenance treatmentMethadone maintenance treatment doseHigher doses of methadoneProspective trialsHighest methadone dosagePost-release outcomesHigher methadone dosesMalaysia’s largest prison.Levels of depressionTreatment of opioid use disorderMonths of releaseDose of methadoneOpioid use disorderLargest prisonHigher dosageIncarcerated peopleIncarceration periodUse disorderMethadone dosageTime-to-event analysis
2023
Application of the multiphase optimisation strategy (MOST) to optimise HIV prevention targeting people on medication for opioid use disorder (MOUD) who have cognitive dysfunction: protocol for a MOST study
Mistler C, Shrestha R, Gunstad J, Collins L, Madden L, Huedo-Medina T, Sibilio B, Copenhaver N, Copenhaver M. Application of the multiphase optimisation strategy (MOST) to optimise HIV prevention targeting people on medication for opioid use disorder (MOUD) who have cognitive dysfunction: protocol for a MOST study. BMJ Open 2023, 13: e071688. PMID: 37399447, PMCID: PMC10314648, DOI: 10.1136/bmjopen-2023-071688.Peer-Reviewed Original ResearchConceptsOpioid use disorderMultiphase optimization strategyCognitive dysfunctionHIV preventionUse disordersPromising biomedical interventionsPre-exposure prophylaxisHIV incidence ratesHIV risk reductionHIV prevention interventionsDrug treatment settingsInstitutional review boardInformed consent formPrEP adherenceHIV prevention contentHIV infectionPrEP uptakeStudy protocolIncidence rateRisk groupsPrevention interventionsPWIDTreatment settingsReview boardEffective interventions
2022
Using nominal group technique to identify barriers and facilitators to preventing HIV using combination same-day pre-exposure prophylaxis and medications for opioid use disorder
Eger WH, Altice FL, Lee J, Vlahov D, Khati A, Osborne S, Wickersham JA, Bohonnon T, Powell L, Shrestha R. Using nominal group technique to identify barriers and facilitators to preventing HIV using combination same-day pre-exposure prophylaxis and medications for opioid use disorder. Harm Reduction Journal 2022, 19: 120. PMID: 36307817, PMCID: PMC9616614, DOI: 10.1186/s12954-022-00703-8.Peer-Reviewed Original ResearchConceptsSame-day prescriptionPre-exposure prophylaxisOpioid use disorderHIV transmissionUse disordersClinical stakeholdersAvailability of providersSystems of careHealth care systemCoordinated careNew practice modelClinical careMedicationsPharmacy deliveryMOUDNominal group techniqueLocal prescribersPWIDSexual riskPrEPCare systemHealth benefitsCareMultiple visitsProphylaxisNurse Practitioner–Led Integrated Rapid Access to HIV Prevention for People Who Inject Drugs (iRaPID): Protocol for a Pilot Randomized Controlled Trial
Khati A, Altice FL, Vlahov D, Eger WH, Lee J, Bohonnon T, Wickersham JA, Maviglia F, Copenhaver N, Shrestha R. Nurse Practitioner–Led Integrated Rapid Access to HIV Prevention for People Who Inject Drugs (iRaPID): Protocol for a Pilot Randomized Controlled Trial. JMIR Research Protocols 2022, 11: e42585. PMID: 36222826, PMCID: PMC9597427, DOI: 10.2196/42585.Peer-Reviewed Original ResearchINTERNATIONAL REGISTERED REPORT IDENTIFIERSame-day PrEPHIV prevention programsPreliminary efficacyTrial designReal-world settingPrevention programsPre-exposure prophylaxis uptakePilot studyProspective pilot studySignificant public health concernOpioid use disorderHIV prevention strategiesHepatitis C virusOutbreak of HIVEvidence-based preventionPublic health concernInstitutional review boardMOUD initiationControlled TrialsPilot RCTC virusOpioid epidemicHIV preventionNurse practitionersLatent profile analysis of data from the brief inventory of neurocognitive impairment (BINI) to develop neuro-cognitive profiles among opioid-dependent patients in drug treatment
Gunstad J, Disabato D, Shrestha R, Sanborn V, Mistler CB, Copenhaver MM. Latent profile analysis of data from the brief inventory of neurocognitive impairment (BINI) to develop neuro-cognitive profiles among opioid-dependent patients in drug treatment. Journal Of Addictive Diseases 2022, 41: 120-127. PMID: 35615880, PMCID: PMC9699904, DOI: 10.1080/10550887.2022.2080626.Peer-Reviewed Original ResearchConceptsLatent profile analysisNeurocognitive dysfunctionBrief inventoryNeuro-cognitive profileNeuro-cognitive impairmentSelf-reported neurocognitive symptomsProfile analysisOpioid-dependent patientsOpioid use disorderTreatment outcomesNeurocognitive impairmentDrug treatment outcomesMultiple domainsTreatment programUse disordersIntervention strategiesIndividual treatment needsNeurocognitive symptomsDrug treatment settingsTreatment settingsMethadone maintenance treatment programAccommodation strategiesModerate concernMaintenance treatment programOptimal treatment outcomesRace, Trust, and COVID-19 Vaccine Hesitancy in People with Opioid Use Disorder
Sullivan MC, Mistler C, Copenhaver MM, Wickersham JA, Ni Z, Kim RS, Shrestha R. Race, Trust, and COVID-19 Vaccine Hesitancy in People with Opioid Use Disorder. Health Psychology 2022, 41: 115-120. PMID: 34855415, PMCID: PMC9754617, DOI: 10.1037/hea0001120.Peer-Reviewed Original ResearchConceptsOpioid use disorderMethadone maintenance programEffective vaccineVaccine hesitancyUse disordersCOVID-19 vaccine hesitancyInjection drug useEffective COVID-19 vaccineCoronavirus disease 2019COVID-19 vaccineCOVID-19Sexual risk behaviorsSocial risk factorsVaccine uptakeRisk factorsVaccination willingnessRisk groupsDisease 2019Psychosocial factorsDrug useProactive outreachPhysician ScaleRisk behaviorsHealth disparitiesVaccineClinical and Demographic Differences in the Willingness to use Self-Administered At-Home COVID-19 Testing Measures among Persons with Opioid use Disorder
Mistler CB, Sullivan M, Wickersham JA, Copenhaver MM, Shrestha R. Clinical and Demographic Differences in the Willingness to use Self-Administered At-Home COVID-19 Testing Measures among Persons with Opioid use Disorder. Substance Use & Addiction Journal 2022, 43: 708-712. PMID: 35100084, PMCID: PMC9725184, DOI: 10.1080/08897077.2021.2007511.Peer-Reviewed Original ResearchConceptsOpioid use disorderCOVID-19 testPrick testUse disordersCOVID-19Older aged participantsTesting measuresSaliva-based testThroat swab samplesCOVID-19 transmissionGreater proportionGreater riskSwab samplesAdverse effectsAged participantsTesting optionsDisadvantaged populationsRacial-ethnic minoritiesWhite participantsDemographic differencesDisordersHome ordersGreater rateTreatmentParticipants
2021
Fentanyl Test Strip Use and Overdose History among Individuals on Medication for Opioid Use Disorder
CB M, AO R, W E, MM C, R S. Fentanyl Test Strip Use and Overdose History among Individuals on Medication for Opioid Use Disorder. Austin Journal Of Public Health And Epidemiology 2021, 8 DOI: 10.26420/austinjpublichealthepidemiol.2021.1117.Peer-Reviewed Original ResearchFentanyl test stripsOpioid use disorderFentanyl useUse disordersTest strip useNon-fatal overdoseDrug overdose deathsNumber of deathsHalf of participantsMajority of participantsOverdose historyOverdose deathsFentanylStrip useLow uptakeDrug supplyMedicationsDeathWidespread educationDisordersParticipantsUseful strategyIndividualsHigh levelsMOUDFentanyl Test Strip Use and Overdose History among Individuals on Medication for Opioid Use Disorder.
Mistler C, Rosen A, Eger W, Copenhaver M, Shrestha R. Fentanyl Test Strip Use and Overdose History among Individuals on Medication for Opioid Use Disorder. Austin Journal Of Public Health And Epidemiology 2021, 8 PMID: 35782633, PMCID: PMC9249264.Peer-Reviewed Original ResearchFentanyl test stripsOpioid use disorderFentanyl useUse disordersTest strip useNon-fatal overdoseDrug overdose deathsNumber of deathsHalf of participantsMajority of participantsOverdose historyOverdose deathsFentanylStrip useLow uptakeDrug supplyMedicationsDeathWidespread educationDisordersParticipantsUseful strategyIndividualsHigh levelsMOUDMethadone within prison and linkage to and retention in treatment upon community release for people with opioid use disorder in Kyrgyzstan: Evaluation of a national program
Bachireddy C, Shrestha R, Bromberg DJ, Azbel L, Kurmanalieva A, Wegman M, Shumskaya N, Rozanova J, Meyer JP, Altice FL. Methadone within prison and linkage to and retention in treatment upon community release for people with opioid use disorder in Kyrgyzstan: Evaluation of a national program. International Journal Of Drug Policy 2021, 101: 103558. PMID: 34915426, PMCID: PMC9998103, DOI: 10.1016/j.drugpo.2021.103558.Peer-Reviewed Original ResearchConceptsHIV statusMean treatment durationOpioid use disorderPositive HIV statusDuration of treatmentMethadone doseHIV incidenceMethadone servicesMethadone treatmentIndependent correlatesHIV preventionUse disordersTreatment durationMethadoneNational programTreatmentHIVAdministrative dataCommunity releaseMonthsKyrgyz prisonsFirst evaluationIncarcerated peopleDurationReleaseAdapting behavioural interventions to compensate for cognitive dysfunction in persons with opioid use disorder
Mistler CB, Shrestha R, Gunstad J, Sanborn V, Copenhaver MM. Adapting behavioural interventions to compensate for cognitive dysfunction in persons with opioid use disorder. General Psychiatry 2021, 34: e100412. PMID: 34504995, PMCID: PMC8370499, DOI: 10.1136/gpsych-2020-100412.Peer-Reviewed Original ResearchCognitive profileBehavioral interventionsCognitive dysfunctionAccommodation strategiesSimilar cognitive profileUse disordersFuture intervention researchSuch behavioral interventionsCognitive demandsExecutive functionBehavioral therapyCognitive functionInformation processingIntervention approachesIntervention researchIntervention placePatient's abilityOpioid use disorderInterventionTreatment outcomesPsychoeducationDisordersResearchMemoryAbilityDeveloping a cognitive dysfunction risk score for use with opioid-dependent persons in drug treatment
Copenhaver MM, Sanborn V, Shrestha R, Mistler CB, Sullivan MC, Gunstad J. Developing a cognitive dysfunction risk score for use with opioid-dependent persons in drug treatment. Drug And Alcohol Dependence 2021, 224: 108726. PMID: 33930640, PMCID: PMC8180490, DOI: 10.1016/j.drugalcdep.2021.108726.Peer-Reviewed Original ResearchConceptsMild cognitive impairmentCognitive dysfunctionRisk scoreDrug treatmentPredictors of MCIOpioid-dependent personsOpioid use disorderPredictive risk scoreMedical chart dataNeuro-cognitive impairmentResource-limited settingsChart dataDrug treatment facilitiesAddiction-related servicesLarger validation studiesPatient demographicsROC curve areaUse disordersTreatment engagementCognitive impairmentPatientsOptimal cutClinical settingLogistic regressionMCI casesDifferential impacts of COVID-19 across racial-ethnic identities in persons with opioid use disorder
Mistler CB, Sullivan MC, Copenhaver MM, Meyer JP, Roth AM, Shenoi SV, Edelman EJ, Wickersham JA, Shrestha R. Differential impacts of COVID-19 across racial-ethnic identities in persons with opioid use disorder. Journal Of Substance Use And Addiction Treatment 2021, 129: 108387. PMID: 34080555, PMCID: PMC8380664, DOI: 10.1016/j.jsat.2021.108387.Peer-Reviewed Original ResearchConceptsOpioid use disorderPublic health responseCOVID-19Use disordersHealth behaviorsNon-prescription drug useRacial-ethnic minoritiesCOVID-19-related impactsMental health statusHealth care accessSexual health behaviorsCOVID-19 testGreater financial burdenRace/ethnicitySample of peopleDirect adverse effectsDrug treatmentCare accessAlcohol consumptionDrug useHealth statusHealth responseHealth disparitiesRisk peopleCOVID-19 pandemic presentsThe Impact of COVID-19 on Access to HIV Prevention Services Among Opioid-Dependent Individuals
Mistler CB, Curley CM, Rosen AO, El-Krab R, Wickersham JA, Copenhaver MM, Khati A, Shrestha R. The Impact of COVID-19 on Access to HIV Prevention Services Among Opioid-Dependent Individuals. Journal Of Community Health 2021, 46: 960-966. PMID: 33770334, PMCID: PMC7996112, DOI: 10.1007/s10900-021-00979-0.Peer-Reviewed Original ResearchConceptsOpioid use disorderHIV prevention servicesSTI testingHIV counselorsPrEP prescriptionPrevention servicesCOVID-19Pre-exposure prophylaxis servicesOpioid use disorder treatmentCOVID-19 pandemicClean injection equipmentOpioid-dependent individualsOpioid-dependent peopleUse disorder treatmentInjection equipmentHIV testingInfection testingBlood testingHIV preventionUse disordersPWIDDisorder treatmentDoctor's appointmentAdverse effectsCase managers
2020
Association between the brief inventory of neurocognitive impairment (BINI) and objective cognitive testing among persons with opioid use disorders in drug treatment
Copenhaver MM, Sanborn V, Shrestha R, Mistler C, Gunstad J. Association between the brief inventory of neurocognitive impairment (BINI) and objective cognitive testing among persons with opioid use disorders in drug treatment. Journal Of Addictive Diseases 2020, 39: 166-174. PMID: 33047651, PMCID: PMC11395862, DOI: 10.1080/10550887.2020.1831129.Peer-Reviewed Original ResearchConceptsMethadone maintenance therapyDrug treatmentNeurocognitive dysfunctionNeurocognitive impairmentOpioid use disorderPossible clinical utilityAccommodation of patientsNIH ToolboxSubjective cognitive dysfunctionMaintenance therapyObjective cognitive testingSpecific neurocognitive profileTreatment outcomesCognitive dysfunctionClinical utilityUse disordersBrief inventoryObjective test performanceDysfunctionCognitive testingCutoff scoreNeurocognitive profileTest batteryObjective performanceImpairmentAwareness about and willingness to use long-acting injectable pre-exposure prophylaxis (LAI-PrEP) among people who use drugs
Shrestha R, DiDomizio EE, Kim RS, Altice FL, Wickersham JA, Copenhaver MM. Awareness about and willingness to use long-acting injectable pre-exposure prophylaxis (LAI-PrEP) among people who use drugs. Journal Of Substance Use And Addiction Treatment 2020, 117: 108058. PMID: 32811633, PMCID: PMC7438607, DOI: 10.1016/j.jsat.2020.108058.Peer-Reviewed Original ResearchConceptsPre-exposure prophylaxisInjectable pre-exposure prophylaxisLAI-PrEPOral pre-exposure prophylaxisLong-term side effectsSelf-reported HIV risk behaviorsBangkok Tenofovir StudyEvidence-based HIVHigh-risk PWUDImportant key populationHIV-negative peopleOpioid use disorderHIV risk behaviorsHIV prevention effortsAddiction treatment programsDaily PrEPOral PrEPAdherence challengesIndependent correlatesFemale sexClinical trialsHIV preventionIndependent factorsSide effectsUse disordersCognitive profiles in persons with opioid use disorder enrolled in methadone treatment
Sanborn V, Gunstad J, Shrestha R, Mistler CB, Copenhaver MM. Cognitive profiles in persons with opioid use disorder enrolled in methadone treatment. Applied Neuropsychology Adult 2020, 29: 462-468. PMID: 32463730, PMCID: PMC7704535, DOI: 10.1080/23279095.2020.1769099.Peer-Reviewed Original ResearchConceptsCognitive profileUse disordersTests of attentionDistinct cognitive profilesCognitive impairmentIntact cognitive functionOpioid use disorderExecutive functionCognitive phenotypesNIH ToolboxSubstance use treatmentCognitive functionImpaired groupAlcohol fourTreatment programPoor treatment outcomesUse treatmentMethadone maintenance treatment programImpairmentMaintenance treatment programDisordersUnderlying structurePersonsTreatment outcomesMore time